D
epression causes significant morbidity in older adults. 1, 2 Although antidepressants and traditional psychotherapy remain mainstays of therapy, cost-effective nonpharmacological treatments are needed, particularly for older adults and minorities. [3] [4] [5] [6] Previous studies have examined the cost-effectiveness of depression treatments involving both pharmacological agents and nonpharmacological programs or models of care, but these studies vary widely with regard to the populations studied and the interventions and economic methods used. Results indicate a wide range of incremental cost-effectiveness ratios (ICERs) ($2,500-460,000/quality-adjusted life year (QALY)). [7] [8] [9] [10] [11] [12] [13] [14] Furthermore, none of these studies have evaluated the cost-effectiveness of home-and communitybased nonpharmacological interventions in older African Americans. This is important because prior studies of older African Americans have demonstrated that depressive symptoms are underdetected and undertreated and that this group may have less access to treatment. 1, [15] [16] [17] [18] As the healthcare system moves toward evidence-based decision-making, research on the cost-effectiveness of new models of mental health care that are accessible to community-dwelling minority populations and that provide nonpharmacological treatment options has been identified as a public health priority. 19, 20 This article reports the cost-effectiveness of one such program-Beat the Blues (BTB)-which was designed for and previously tested in a randomized control trial of African Americans. This is the first study to the knowledge of the authors to examine the cost-effectiveness of a novel nonpharmacological approach to address depressive symptoms in this population. Furthermore, the study has important methodological value in that detailed cost-effectiveness findings are reported using a robust array of outcome measures, including QALYs and the remission and reduction of depressive symptoms.
METHODS
The BTB trial was a collaboration between academic research centers and a senior center in Philadelphia. Participants were recruited using print media, presentations to community groups, senior center membership, and a home support program for temporarily medically compromised older adults. Participants underwent two sequential depression screenings by a trained screener over 2 weeks using the Patient Health Questionnaire-9 (PHQ-9), a validated nine-item self-report measure widely used in clinical and research contexts. [21] [22] [23] Candidates who scored 5 or more on both PHQ-9 administrations and who were African American, aged 55 and older, English speaking, and cognitively intact (Mini-Mental State Examination score >24) were eligible to participate. Study participants were randomized to receive the BTB intervention or to a wait list that received the intervention in its entirety after the 4-month follow-up (control group). Interviewers blinded to group assignment assessed all participants at baseline and 4 and 8 months.
BTB Intervention
Treatment components of BTB that reflected best evidence and preferred management strategies of the targeted population were selected. Previous research and focus group work conducted to inform intervention development suggested that older African Americans prefer nonpharmacological strategies as first-line treatment and tend to use active management strategies such as engaging in activities to manage daily life stressors. [24] [25] [26] Previous research has also suggested that depressive symptoms in this group may reflect a confluence of external contextual factors such as poor self-management of chronic disease or financial strain that warrant consideration and modification as part of a depression treatment program.
In up to 10 sessions over 4 months, BTB interventionists (trained licensed social workers) provided depression education and care management, made referrals and linkages, taught stress reduction techniques, and used behavioral activation to help participants achieve self-identified goals. 25 BTB does not use medications, but participants may have sought and received medication from a medical doctor before, during, or after study participation.
Main efficacy findings from the trial have been previously reported and indicated that BTB reduced depressive symptoms, anxiety, and functional difficulties; improved quality of life (QoL), behavioral activation, and well-being; and enhanced depression knowledge. In addition, at 4 months, 44% of BTB participants were in remission, compared with 27% of wait-listed controls. 27 The cost-effectiveness analysis was added to the main trial after recruitment was under way. Costs were reported at baseline and 4 months (US$ 2010) and included three main categories: BTB intervention (screening, intervention delivery, supervision), healthcare service use (inpatient, outpatient, medication costs), and formal caregiving and social service use. Work productivity losses were also captured but were excluded post hoc because only 12 participants were working. A detailed explanation of cost measures is provided in Supporting Information Appendix S1.
The primary effectiveness measure used in the cost-effectiveness analysis was QALYs, which are recommended as the preferred outcome measure in societal cost-effectiveness studies. 28 QALYs were measured at baseline and 4 months using the Euro-QoL 5D (EQ-5D), which includes five domains (mobility, self-care, daily activities, pain and discomfort, depression and anxiety) scored on three levels (no, some, or extreme problems). The study was powered to detect a EQ-5D score difference of 0.098 between BTB and wait-list control with a power of 0.8, which is within reasonable expectations based on prior research. A scoring algorithm based on U.S. preference weights was used to convert EQ-5D health states to utilities. 29 The EQ-5D was chosen because of the availability of U.S. scoring and the instrument's simplicity. Owing to its limited number of domains and levels within each domain, it was decided also to capture QALYs using the Health Utilities Index version 3 (HUI-3). HUI-3 consists of 40 items that capture eight attributes of health-related QoL: vision, hearing, speech, ambulation, dexterity, emotion, cognition, and pain. 30 The scoring algorithm was obtained from Health Utilities Inc. and is based on Canadian health preference weights. Utility scores from both instruments range from 0 to 1, with higher scores indicating better quality-adjusted life. To convert utilities into QALYs, the area under the curve of observed utility was calculated for the 4-month period, reflecting the change in utility that each group experienced.
Cost-effectiveness was also calculated using clinical measures, specifically, cost per depression remission and cost per reduction in depressive symptoms. Reduction of symptom severity and remission and reduction of depressive symptoms were also the primary outcomes of the main trial as measured using the PHQ-9. Using a recall period of 2 weeks for the presence of nine symptoms, the PHQ-9 yielded two scores: a symptom severity score (0-27) and a diagnostic category (minimal to no symptoms (0-4), mild depression (5-9), moderate depression (10) (11) (12) (13) (14) , moderately severe depression (15) (16) (17) (18) (19) , and severe depression (20) (21) (22) (23) (24) (25) (26) (27) ) mapping onto the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. 31 Consistent with the main trial and PHQ-9 scoring guidelines, remission was defined as a score less than 5 at 4 months.
Cost-effectiveness was evaluated from a societal perspective and based on recommendations of the U.S. Public Health Service Panel on Cost-Effectiveness 28 using the ICER shown below:
In this equation, the total cost and effectiveness differences of BTB and for wait-list control were calculated as the costs for the numerator and effectiveness for the denominator for each of these two groups at 4 months minus baseline, representing a difference-in-difference approach. The denominator represented the change in outcome (baseline to 4 months) and was tested using the four effectiveness measures previously described: EQ-5D QALYs, HUI-3 QALYs, percentage experiencing clinical remission of depressive symptoms (PHQ-9 <5), and percentage experiencing reduction of depressive symptoms (improvement in depression as indicated by movement of ≥1 PHQ-9 severity categories).
Sensitivity analyses were performed on the main costeffectiveness ICER (EQ-5D cost/QALY). A probabilistic sensitivity analysis (PSA; Sensitivity Analysis 1) was conducted using distributions around the cost and effectiveness measures to make a probabilistic statement regarding the ICER. This type of analysis is critical for trial-based cost-effectiveness analyses because sample sizes are typically too small to provide certainty in the base case ICER. The PSA was a simulation performed using TreeAge Pro 2009 (TreeAge Software, Inc., Williamstown, MA) that consisted of 1,000 random iterations with the goal of determining the likelihood that BTB was more cost-effective than the wait-list control.
A second sensitivity analysis (Sensitivity Analysis 2) was performed to determine how the ICER would change if specific components of BTB intervention costs were modified. This consisted of a series of univariate sensitivity analyses in which each component cost of BTB was varied by AE1 standard deviation of its mean to reveal which aspects of the program (interventionist travel, program delivery, training) could be streamlined to maximize cost-effectiveness.
RESULTS

Participant Characteristics
Over a 2-year period, 703 older adults were screened for the trial, of whom 241 (34.3%) were eligible and 208 (86.3%) were willing to participate. Of these, 129 (62.0%) were included in the cost-effectiveness study. The baseline characteristics of the cost-effectiveness sample were statistically similar to those of the pre-cost-effectiveness sample (n = 79) except percentage of participants reporting pain medication. The pre-cost-effectiveness sample had higher percentage reporting pain medication, probably due to a change in the way pain medications were recorded for the cost-effectiveness sample. At 4 months, the cost study included 57 participants in the BTB and 56 in the wait-list control (Figure 1) .
Characteristics of the cost study sample (n = 129) were as follows. Mean age was 68.7, 79.1% were female, 45.7% had at least a high school education, and mean baseline PHQ-9 score was 12.6. There were no statistically significant differences at baseline between those randomized to BTB (n = 68) and those randomized to the wait-list control (n = 61) except that fewer BTB participants lived alone than did those in the wait-list control (P = .002) ( Table 1) .
Cost of BTB and Service Use
The total cost of implementing BTB was $146/person per month or $585/person over the 4 months, and the total cost difference at 4 months (BTB-wait-list control) was $491. The costs of the intervention were the main determinant of this additional cost in the BTB treatment group. Differences in service use costs were not statistically significant. The cost of depression-related doctor calls and visits (mean/person during the 4 months) for the BTB treatment group was $3.96, compared with $2.68 per wait-list control. Medication costs for the BTB treatment group were $159.32 (mean/person during the 4 months), versus $196.97 per wait-list control. For caregiver services, BTB treatment group costs were $95.54 (mean/person during the 4 months), versus $38.12 per wait-list control. Spending on social services for BTB participants was also slightly more than for wait-list controls (mean/person during the 4 months $96.86 vs $89.98, respectively). Costs of complementary and alternative medicines were similar for the BTB treatment group and wait-list control.
Effectiveness
At baseline, the BTB group's EQ-5D utility (0.566) was slightly lower than that of wait-list controls (0.582; not statistically significant). By 4 months, the BTB group experienced a mean EQ-5D utility of 0.665 (0.099 increase), and the wait-list group experienced a mean EQ-5D utility of 0.635 (0.053 increase). For HUI-3, at baseline the BTB group's utility (0.335) was lower than that of the wait-list control (0.432; not statistically significant). By 4 months, the BTB group's utility was 0.479 (0.144 increase), whereas the utility for wait-list controls was 0.496. Thus, the magnitude of utility increase for HUI-3 was greater than that of EQ-5D for both study groups.
In terms of clinical effectiveness, 71.9% of BTB costeffectiveness participants experienced a reduction in depressive symptoms to a lower PHQ-9 severity, compared with 60.7% of wait-list control participants. In addition, 38.6% of BTB participants experienced clinical remission of depression at 4 months, compared with 28.6% of waitlist control participants.
Cost-Effectiveness
The ICERs indicating incremental cost-effectiveness of BTB vs. wait-list control were $64,896/QALY (EQ-5D) and $36,875/QALY (HUI-3). The ICER for clinical depression measures was $4,384 per participant experiencing a reduction in depressive symptoms to a lower severity ICER ¼ Total Cost Difference BTB À Total Cost Difference waitÀlist control Effectiveness Difference BTB À Effectiveness Difference waitÀlist control category, and $4,911/participant experiencing remission of depressive symptoms (Table 2) .
Sensitivity analyses conducted using the ICER resulting from our main health utility measure, cost/EQ-5D derived QALY (Sensitivity Analysis 1, shown in Figure 2 ), revealed a majority (91%) of the simulated ICERs in the upper right quadrant of the cost-effectiveness plane, indicating that, in most cases, BTB treatment costs more than wait-list control but is more effective.
For Sensitivity Analysis 2, when the cost of each component of BTB was modified within 1 standard deviation of its mean to determine which had the greatest effect on the ICER, it was found that travel and BTB delivery were most significant (Figure 3) . Specifically, when interventionist travel costs (mileage + labor) varied from $37 to $385, the ICER ranged from $42,000/QALY to $88,000/QALY. When the cost of BTB program delivery (e.g., home sessions) varied from $64 to $330, the ICER ranged from $47,000/QALY to $82,000/QALY. Materials and interventionist follow-up contacts also affected the ICER but to a lesser extent.
DISCUSSION
This is the first cost-effectiveness analysis of a home-based nonpharmacological depression program designed for older African Americans, a growing population for which disparities in access to and receipt of mental health treatments persist. The ICERs from two measures were $64,896/ QALY (EQ-5D) and $36,875/QALY (HUI-3). Based on these ICERs, BTB's incremental cost-effectiveness falls within the societal cost-effectiveness funding thresholds generally reported in the literature ($50,000-100,000/ QALY) 32 and is in the range of ICERs previously reported for pharmacological and nonpharmacological depression interventions. [7] [8] [9] [10] [11] [12] [13] [14] Thus, BTB's cost-effectiveness may support its adoption for older African Americans with depressive symptoms, but ultimately the decision to adopt it will depend upon what cost/QALY decision-makers are willing to pay.
More participants reported taking antidepressants at baseline in BTB than in the wait-list control group. Hence, it is reasonable to question whether this influenced the QALY improvements in BTB. This was explored, and it was found that at 4 months, the number reporting antidepressants decreased in BTB and increased in wait-list control. This shift makes it difficult to determine the exact influence of antidepressants on the findings, but it is unlikely that it was a major factor. Also, the decline in medication use in the treatment group and an increase in medication use in the wait-list control group suggests that further research on the effect of BTB on medication use should be examined.
Given the popularity of medications, it is worth considering how BTB's cost-effectiveness compares specifically with that of antidepressants. Cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care was compared with that of supportive care alone for mild to moderate depression, and ICERs of $32,496/QALY to $48,744/QALY were reported. 9 A Canadian study compared the incremental cost-effectiveness of duloxetine with that of extended-release venlafaxine using a decision analytic model. The ICER of duloxetine and extended-release venlafaxine was estimated at $20,290/QALY. 13, 33 Another study compared the cost-effectiveness of fluoxetine alone and of fluoxetine in combination with a cognitive behavioral therapy approach, which ranged from $24,000/ QALY to $123,000/QALY, with that of placebo. 14 The current study also reported cost-effectiveness from a clinical perspective using remission and reduction of depressive symptoms; ICERs were found to range from $2,000 to $5,000. Few studies have reported ICERs this way. One study found the cost per successfully treated severely depressed individual (based on achievement of remission) to be $3,537 for escitalopram and $4,673 for citalopram. 34 BTB's cost-effectiveness compares favorably with these values.
The current analysis was comprehensive, but U.S. healthcare stakeholders-particularly health plans-have a budgetary impetus to make decisions based on cost rather than cost-effectiveness. Although BTB would appear to be a Range 1 to 5 (1 = no difficulty, 5 = prohibitive difficulty).
expensive because of travel to participants' homes and time requirements, it costs only $146/participant per month for 4 months. This is comparable with the average wholesale prices of certain brand name antidepressants. 35 Despite BTB's competitive costs, it is worth exploring whether the program can be delivered using fewer visits without compromising its effectiveness. In addition, there may be opportunities to centralize services, deliver aspects of the program remotely, or create economies of scale in training and supervision.
Considering these findings, it could be argued that health plans that reimburse for antidepressants and traditional psychotherapy should expand their benefits to include tested nonpharmacological programs such as BTB. Such programs are an important treatment option for older adults, especially those who cannot tolerate antidepressant side effects or are at risk for polypharmacy because of multiple concomitant medications.
This study has significant methodological importance. First, cost-effectiveness was reported using a . Diagram shows a one-way sensitivity analysis for the components of the BTB intervention that, when varied between AE 1 standard deviation, has the greatest effect on the main Euro Quality of Life (EQ)-5D-derived incremental cost-effectiveness ratio (ICER). Dollar amounts indicate the expected ICER given the low and high estimates for the four most sensitive cost domains. EV = expected value.
variety of measures to fully inform healthcare decisionmakers. Because the results of applied health economic analyses can differ widely based on what interventions are tested, what costs are included, and what outcomes are used, analyzing an array of measures is critical to advancing the field. This study demonstrated that choice of utility instrument can significantly affect cost-effectiveness calculations. The magnitude of utility improvements from the EQ-5D (0.0076; 2.77 quality-adjusted life days) was less than that of the HUI-3 (0.0133; 4.85 qualityadjusted life days). This difference, albeit small, may be clinically significant to individuals, but to a healthcare decision-maker who is primarily interested in cost-effectiveness, the EQ-5D-derived ICER is nearly $30,000 more than HUI-3 and raises the question as to which measure should be chosen for making programmatic decisions. One explanation for the utility differences may be that HUI-3 is more sensitive to change than EQ-5D in the BTB population; HUI-3 contains many more items relevant to the intervention, and its domains are specifically relevant to older adults (e.g., cognition, ambulation, sensory domains encompassing vision and hearing). In future studies, it may be useful to use a new version of EQ-5D that contains five response levels (EQ-5D-5L), potentially offering greater precision. 36 
Limitations
There are several limitations to this analysis. First, findings may not be generalizable to other populations (e.g., Caucasians or other minorities), and the 4-month time horizon prohibits a determination of BTB's long-term cost-effectiveness, although the main trial indicated that treatment benefits endured from 4 to 8 months for the BTB group without further intervention. Second, wait-list control participants experienced improvements in depressive symptoms and improvements in quality-adjusted life, perhaps as a consequence of taking part in the trial. Therefore, the findings may not represent the difference in cost-effectiveness between BTB and true usual care.
The sample size for this study was smaller than that of the BTB main trial, but it met the recruitment goals for the cost-effectiveness study. Furthermore, the effect of uncertainty was modeled by performing comprehensive sensitivity analyses, consistent with best practices in economic evaluation. 28 Because a goal of cost-effectiveness studies is to inform decision-makers by providing a range of results, sensitivity analyses are critical. In addition, the sample for the EQ-5D was slightly larger than for the HUI-3; a post hoc review of the data collection forms suggests that interviewers in some cases had difficulty administering the HUI-3, resulting in 21 of 226 (9.3%) of HUI-3 batteries being unscorable (10/113 baseline, 11/113 at 4 months). Future research involving HUI-3 would benefit from more-focused interviewer training to ensure smooth administration. Finally, certain categories of service use costs (health care, caregiving, social services) were captured using 30-day recall, which was shorter than the 4-month period between assessments. For these categories, it was conservatively assumed that use during the past 30 days represented all use during the 4 months, but it is possible that some participants sought more-frequent care.
CONCLUSION
BTB is a novel nonpharmacological program involving a partnership with a senior center for its delivery. Based on commonly stated willingness-to-pay thresholds, BTB may be a cost-effective treatment option for managing depressive symptoms in older African Americans. Findings suggest that the program may have an acceptable costeffectiveness, although more-robust examination of the program in a larger, longer study would be worthwhile. Potential opportunities to reduce BTB costs were also identified. Although BTB was tested in an older AfricanAmerican urban community, its focus on addressing social ecological factors that affect mood may be a highly relevant treatment approach for other minority populations and individuals with low socioeconomic status. As the population ages and healthcare budgets experience continued strains, economic analyses such as these and for diverse older adult populations are critically needed to understand the value of nonpharmacological modalities to healthcare decision-makers.
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